BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 11, 2006
 |  BioCentury  |  Strategy

As the CRO flies

Oncodesign S.A. is planning to join other CROs in migrating its business model toward co-development deals with biotech companies. The cancer CRO also hopes to leverage its relationships with pharma to help find marketing partners.

"We're launching a co-development strategy," Bertrand Merot, VP of corporate development, told BioCentury. "We're setting up offices in Canada and we're proposing to biotech companies and universities in North America and Europe to share the risk of product development."

Oncodesign (Dijon, France) evaluates new cancer...

Read the full 381 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >